Rep. Gilbert Ray Cisneros, Jr. Buys Bristol Myers Squibb Company (NYSE:BMY) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bristol Myers Squibb stock on December 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Bristol Myers Squibb Trading Up 1.8%

BMY stock traded up $1.02 during midday trading on Wednesday, hitting $56.94. 4,402,897 shares of the company’s stock were exchanged, compared to its average volume of 11,953,143. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The company has a market cap of $115.92 billion, a PE ratio of 19.24, a price-to-earnings-growth ratio of 9.23 and a beta of 0.29. The stock’s fifty day moving average price is $51.33 and its 200-day moving average price is $47.94.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same quarter in the prior year, the company earned $1.80 EPS. The company’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is 85.14%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds have recently made changes to their positions in BMY. Brighton Jones LLC lifted its holdings in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Modern Wealth Management LLC boosted its holdings in Bristol Myers Squibb by 16.5% in the first quarter. Modern Wealth Management LLC now owns 18,426 shares of the biopharmaceutical company’s stock valued at $1,124,000 after acquiring an additional 2,608 shares in the last quarter. HBW Advisory Services LLC increased its position in shares of Bristol Myers Squibb by 9.4% during the second quarter. HBW Advisory Services LLC now owns 4,715 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 407 shares during the period. Fiduciary Financial Group LLC raised its position in shares of Bristol Myers Squibb by 59.7% in the 2nd quarter. Fiduciary Financial Group LLC now owns 7,191 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 2,688 shares in the last quarter. Finally, TruWealth Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 23.3% during the 2nd quarter. TruWealth Advisors LLC now owns 249,589 shares of the biopharmaceutical company’s stock valued at $11,553,000 after buying an additional 47,163 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wells Fargo & Company boosted their target price on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $37.00 price target (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $56.86.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.